Quantcast

Latest Tolerx Inc. Stories

2011-04-05 08:00:00

CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today presented results from preclinical studies with 2F8, a murine analog of TRX518, a first-in-class immunomodulatory agent currently in a Phase 1 clinical study for the treatment of cancer.

2011-03-11 08:02:00

CAMBRIDGE, Mass. and LONDON, March 11, 2011 /PRNewswire/ -- Tolerx, Inc.

2010-08-04 08:08:00

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the appointment of Antonin (Tony) de Fougerolles, Ph.D., as Chief Scientific Officer. Dr.

2010-06-28 06:00:00

CAMBRIDGE, Mass., June 28 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes.


Word of the Day
abactinal
  • Pertaining to the surface or end opposite to the mouth in a radiate animal.
The word 'abactinal' comes from a Greek root meaning 'ray' and a Latin prefix meaning 'away'.
Related